A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects with Advanced Solid Tumors.

Trial Profile

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Adult Subjects with Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs MEDI 0639 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 07 Jun 2016 Results of a sub-group analysis from patients with small-cell lung cancer (n=9) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 27 Apr 2016 Status changed from recruiting to completed.
    • 06 Aug 2015 Planned End Date changed from 1 Nov 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top